The vedolizumab market is expected to increase from USD 6.31 billion in 2025 to USD 11.55 billion by 2034, growing at a CAGR of 6.95% throughout the forecast period from 2025 to 2034.

Vedolizumab Market Statical Scope

Vedolizumab Market Share, By Type

Reasons:

• Intravenous Infusion (65%): It remains the dominant delivery method due to its established clinical acceptance, faster onset of action, and availability in hospital/clinic settings. Physicians still prefer infusion therapy for severe ulcerative colitis and Crohn’s disease cases.
• Injection Pen (35%): Growing adoption is driven by patient preference for convenience, self-administration at home, and reduced hospital visits. The rising trend in biologics moving towards patient-friendly formats is boosting this segment.

Vedolizumab Market Share, By Application

Reasons:

• Ulcerative Colitis (52%): Higher prevalence rates, better diagnosis rates, and more clinical trials supporting vedolizumab use for UC make it the largest share.
• Crohn's Disease (38%): Significant but lower than UC, since biologics for Crohn’s often face more competition from alternatives like adalimumab and infliximab.
• Others (10%): Includes off-label uses and emerging indications. Growth is slower due to limited clinical validation.

Vedolizumab Market Shate, By Region

Reasons:

• North America (36%): Strong dominance due to high prevalence of IBD, advanced healthcare infrastructure, and favorable reimbursement for biologics.
• Europe (28%): High adoption rates supported by government healthcare programs, but slightly behind North America due to stricter regulatory processes.
• Asia-Pacific (25%): Fastest growing region driven by rising diagnosis rates, increasing biologics adoption, and healthcare spending in countries like China, Japan, and India.
• Latin America (5%): Limited market penetration due to affordability challenges and lower diagnosis rates.
• Middle East & Africa (6%): Growing access to advanced biologics, but constrained by affordability and lack of widespread IBD awareness.

Vedolizumab Market Companies

• Takeda Pharmaceutical Company Limited
• LGM Pharma
• Shanghai Minbiotech
• Beijing Mesochem Technology
• Patheon
• Takeda Pharmaceutical Company Limited
• Alvotech
• Advanz Pharma
• AbbVie (Humira)
• Johnson & Johnson (Stelara)
• Merck & Co. (Remicade)
• Bristol Myers Squibb (Zeposia)
• Eli Lilly (Mirikizumab)
• Roche (Rinvoq)
• Gilead Sciences (Filgotinib)
• Pfizer (Xeljanz)
• Mitsubishi Tanabe Pharma
• UCB Pharma

Vedolizumab Market Segmentations

By Type

• Intravenous Infusion
• Injection Pen

By Application

• Crohn's Disease
• Ulcerative Colitis
• Others

By Region

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East and Africa

List of Tables

• Global Market Overview
  • Table 1: Global Vedolizumab Market Size (2024–2034, USD Billion)
    • Base Year (2024) Market Size
    • Forecast Year (2034) Market Size
    • CAGR (2024–2034)
• By Type
  • Table 2: Vedolizumab Market Size by Type (2024–2034, USD Million)
    • Intravenous Infusion
    • Injection Pen
    • Total
  • Table 3: Vedolizumab Market Share by Type (%) – 2024
  • Table 4: Vedolizumab Market Share by Type (%) – 2029
  • Table 5: Vedolizumab Market Share by Type (%) – 2034
• By Application
  • Table 6: Vedolizumab Market Size by Application (2024–2034, USD Million)
    • Ulcerative Colitis
    • Crohn’s Disease
    • Others
    • Total
  • Table 7: Vedolizumab Market Share by Application (%) – 2024
  • Table 8: Vedolizumab Market Share by Application (%) – 2029
  • Table 9: Vedolizumab Market Share by Application (%) – 2034
• By Region
  • Table 10: Vedolizumab Market Size by Region (2024–2034, USD Million)
    • North America
    • Europe
    • Asia-Pacific
    • Latin America
    • Middle East & Africa
  • Table 11: Vedolizumab Market Share by Region (%) – 2024
  • Table 12: Vedolizumab Market Share by Region (%) – 2029
  • Table 13: Vedolizumab Market Share by Region (%) – 2034

List of Figures

• Global Market Trends
  • Figure 1: Global Vedolizumab Market Size (2024–2034, USD Billion) – Line Graph
  • Figure 2: Global Vedolizumab Market CAGR (2024–2034) – Growth Trend
• By Type
  • Figure 3: Vedolizumab Market Share by Type (%) – 2024 (Pie Chart)
  • Figure 4: Vedolizumab Market Share by Type (%) – 2029 (Pie Chart)
  • Figure 5: Vedolizumab Market Share by Type (%) – 2034 (Pie Chart)
  • Figure 6: Vedolizumab Market Size by Type (2024–2034, USD Million) – Bar/Stacked Graph
• By Application
  • Figure 7: Vedolizumab Market Share by Application (%) – 2024 (Pie Chart)
  • Figure 8: Vedolizumab Market Share by Application (%) – 2029 (Pie Chart)
  • Figure 9: Vedolizumab Market Share by Application (%) – 2034 (Pie Chart)
  • Figure 10: Vedolizumab Market Size by Application (2024–2034, USD Million) – Line Graph
• By Region
  • Figure 11: Vedolizumab Market Share by Region (%) – 2024 (Pie Chart)
  • Figure 12: Vedolizumab Market Share by Region (%) – 2029 (Pie Chart)
  • Figure 13: Vedolizumab Market Share by Region (%) – 2034 (Pie Chart)
  • Figure 14: Vedolizumab Market Size by Region (2024–2034, USD Million) – Stacked Column Chart
  • Figure 15: Regional Growth Trend (CAGR %) Comparison (2024–2034)